CERo Therapeutics, Inc.

SAN FRANCISCO, CA · Founded 2016 · Biotech · Public

Multi-functional engineered T cells for cancer immunotherapy

Claim this profile

Follows are private to you and power your alerts

Updated · cero.bio

Sector
Biotech
Headquarters
SAN FRANCISCO, CA
Founded
2016
Latest Form D
$43M, Nov 2019
Total capital
$45M
Grants
—
No SBIR or STTR on record
Sector median 1 award
Raised
$45M
2 Form D · Nov 2019
83 months since last filing
Contracts
—
No federal contracts on record
Patents
40
2 granted · 38 pending
20× sector median 2 patents

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history, newest first
DateEventSourceAmount
Private capital raisedForm D · SEC$43,249,966
Private capital raisedForm D · SEC$1,399,999
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3388Life Biosciences LLC—$54M
3389PhaseBio Pharmaceuticals Inc—$64M
3390OPUS GENETICS INC.—$47M
3391CERo Therapeutics, Inc.—$45M
3392Forte Biosciences—$44M
3393Oncotelic Therapeutics, Inc.—$40M
3394ADVANTAGENE, INC—$36M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 6 related persons
  • Daniel CoreyDirector · Executive Officer · Promoter
  • Jordan CoreyExecutive Officer · Promoter
  • Lawrence CoreyDirector · Executive Officer · Promoter
  • Stan RiddellDirector
  • Stuart SloanDirector
  • Heather TurnerDirector

Patents

USPTO · 2 granted of 40
  • Chimeric Engulfment Receptor Moleculesapplication
  • Chimeric TIM4 Receptors And Uses Thereofapplication
  • Chimeric Engulfment Receptor Molecules And Methods Of Usegranted
  • Chimeric Engulfment Receptor Moleculesgranted
  • Bivalent Chimeric Engulfment Receptors And Uses Thereofapplication
  • Expression Vectors For Chimeric Engulfment Receptors, Genetically Modified Host Cells, And Uses Thereofapplication
  • Chimeric Engulfment Receptors And Uses Thereof For Neurodegenerative Diseasesapplication
  • Chimeric Engulfment Receptor Moleculesapplication
  • ANTI-CD72 Chimeric Receptors And Uses Thereofapplication
  • Chimeric Tim Receptors And Uses Thereofapplication
  • Compositions And Methods For Enhancing CCR7 Expressing T Cells Or CD4/CD8 T Cell Ratio With Chimeric TIM4 Receptors In Combination With Inhibitors Of Poly (adp-ribose) Polymeraseapplication
  • ANTI-CD72 Chimeric Receptors And Uses Thereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.